SEC Form 4 · accession 0001562180-17-003343
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shalini Sharp
Director
Period of report
Oct 26, 2017
Accepted (ET)
Oct 27, 2017 · 4:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $10.47 | Oct 26, 2017 | A | 25,000 | A | Oct 26, 2018 | Oct 26, 2027 | Common Stock | 25,000 | 25,000 | D |
| Restricted Stock UnitsF1 | $0.00 | Oct 26, 2017 | A | 5,000 | A | Oct 26, 2018 | — | Common Stock | 5,000 | 5,000 | D |
Explanation of responses
- F1RSUs awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The units vest and will be settled in stock on October 26, 2018, subject to continued service on Array's board of directors.